Repligen Corporation

$116.76
(as of Jun 23, 11:47 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Repligen Corporation

Stock Price
$116.76
Ticker Symbol
RGEN
Exchange
NASDAQ

Industry Information for Repligen Corporation

Sector
Healthcare
Industry
Medical Instruments & Supplies

Company Description for Repligen Corporation

Country
USA
Full Time Employees
1,778

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Fundamentals for Repligen Corporation

Market Capitalization
$7,708,321,280
EBITDA
$113,392,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
80.65
Earnings per Share
$-0.41
Earnings per Share Estimate Next Year
Profit Margin
-3.53%
Shares Outstanding
56,183,100
Percent Owned by Insiders
6.44%
Percent Owned by Institutions
103.30%
52-Week High
52-Week Low

Technical Indicators for Repligen Corporation

50-Day Moving Average
200-Day Moving Average
RSI
39.78
5.34

Analyst Ratings for Repligen Corporation

Strong Buy
9
Buy
4
Hold
6
Sell
0
Strong Sell
0

News About Repligen Corporation

Jun 16, 2025, 8:09 AM EST
BOSTON - 908 Devices Inc. See more.
Jun 10, 2025, 12:38 AM EST
Running at a loss can be a red flag. See more.
Jun 5, 2025, 7:37 AM EST
The United States market has experienced a steady climb, rising 1.4% in the last week and showing a robust 12% increase over the past year, with earnings projected to grow by 15% annually. See more.
Jun 4, 2025, 11:36 PM EST
Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season. See more.